Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: Pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system

British Journal of Haematology

Volumn 115, Issue 4, 2001, Pages 983-990

  Albertsen, Birgitte Klug ^a,b   Schrøder, Henrik ^b   Ingerslev, Jørgen ^b   Jakobsen, Preben ^a   Avramis, Vassilios I ^c   Müller, Hans Joachim ^d   Carlsen, Niels T ^e   Schmiegelow, Kjeld ^f  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f Rigshospitalet   (Denmark)

Author keywords

ASNase Medac; Erwinia ASNase; i.m. administration; Pharmacokinetics; Side effects

Indexed keywords

ALBUMIN; ANTITHROMBIN III; ASPARAGINASE; ASPARAGINASE ANTIBODY; ASPARAGINASE MEDAC; ASPARAGINE; ENZYME ANTIBODY; ERWINIA ASPARAGINASE; FIBRINOGEN; PLASMINOGEN; PROTEIN C; PROTHROMBIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ENZYME ACTIVITY; HUMAN; HYPERSENSITIVITY; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ABSORPTION; ANTIBODIES; ASPARAGINASE; ASPARAGINE; BACTERIAL PROTEINS; BIOLOGICAL AVAILABILITY; BLOOD COAGULATION; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; ERWINIA; ESCHERICHIA COLI; HUMANS; INJECTIONS, INTRAMUSCULAR; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LIVER; LIVER FUNCTION TESTS; PILOT PROJECTS; REGRESSION ANALYSIS; REMISSION INDUCTION;

EID: 0035672697     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.03148.x     Document Type: Article

References (30)

1. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia
2. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukemia
3. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia
4. Comparative pharmacokinetic studies of three asparaginase preparations
5. Pharmacokinetics and drug monitoring of L-asparaginase treatment. International
6. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations
7. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effect
8. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement
9. Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia culture
10. Asparagine synthetase activity in paediatric acute leukaemias: aML-M5 subtype shows lowest activity
11. Non-randomised study comparing toxicity of Escherichia coli and Erwinia Asparaginase in children with leukemia
12. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma
13. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children-evidence of a complement-mediated mechanism
14. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia
15. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia
16. Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration
17. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic Countries
18. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-Asparaginase: A GIMEMA study
19. Hemostasis in childhood acute lymphoblastic leukemia: Coagulopathy induced by disease and treatment
20. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia
21. Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL
22. Changes in coagulation and fibrinolysis in childhood ALL: A two-step dose reduction of one E.coli asparaginase preparation
23. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase
24. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans
25. Minimal effects of E.coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: A randomized study
26. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E.coli L-asparaginase as first exposure
27. Changes in blood coagulation in treatment with ALL-BFM-90 and NHL-BFM-90 protocols
28. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols
29. Anti-asparaginase antibodies following E.coli asparaginase therapy in pediatric acute lymphoblastic leukemia